Metabolic interactions between cysteamine and epigallocatechin gallate. Issue 3 (1st February 2017)

• Record Type: Journal Article
• Authors: Izzo, Valentina; Pietrocola, Federico; Sica, Valentina; Durand, Sylvère; Lachkar, Sylvie; Enot, David; Bravo-San Pedro, José Manuel; Chery, Alexis; Esposito, Speranza; Raia, Valeria; Maiuri, Luigi; Maiuri, Maria Chiara; Kroemer, Guido
• Is Part Of: Cell cycle. Volume 16:Issue 3(2017)
• Page Start: 271
• Page End: 279
• Publication Date: 2017-02-01
• Subjects: acetylation -- cysteamine -- cystic fibrosis -- EP300 -- epigallocatechin gallate -- metabolic flux -- metabolic profiling; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2016.1249550
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Phase II clinical trials indicate that the combination of cysteamine plus epigallocatechin gallate (EGCG) is effective against cystic fibrosis in patients bearing the most frequent etiological mutation (CFTRΔF508). Here, we investigated the interaction between both agents on cultured respiratory epithelia cells from normal and CFTRΔF508-mutated donors. We observed that the combination of both agents affected metabolic circuits (and in particular the tricarboxylic acid cycle) in a unique way and that cysteamine plus EGCG reduced cytoplasmic protein acetylation more than each of the 2 components alone. In a cell-free system, protein cross-linking activity of EGCG was suppressed by cysteamine. Finally, EGCG was able to enhance the conversion of cysteamine into taurine in metabolic flux experiments. Altogether, these results indicate that multiple pharmacological interactions occur between cysteamine and EGCG, suggesting that they contribute to the unique synergy of both agents in restoring the function of mutated CFTRΔF508.